Pierre Fabre

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

Retrieved on: 
Thursday, February 15, 2024
ED, Volunteering, DSM-IV codes, Patient, Policy, Knowledge, Hypohidrotic ectodermal dysplasia, Pierre Fabre, Pharmaceutical industry

This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community.

Key Points: 
  • This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community.
  • The ED patient community had already greatly contributed to advancing knowledge in XLHED, prior to EspeRare's involvement.
  • When the Foundation EspeRare took over in 2018, the ED patient groups were the first to be on-boarded.
  • "Pierre Fabre's commitment to this groundbreaking program is rooted in our mutual dedication to the patient community.

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

Retrieved on: 
Thursday, February 15, 2024
ED, Volunteering, DSM-IV codes, Patient, Policy, Knowledge, Hypohidrotic ectodermal dysplasia, Pierre Fabre, Pharmaceutical industry

This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community.

Key Points: 
  • This distinction recognises Pierre Fabre and the EspeRare Foundation's collaboration with the Ectodermal Dysplasia (ED) patient community.
  • The ED patient community had already greatly contributed to advancing knowledge in XLHED, prior to EspeRare's involvement.
  • When the Foundation EspeRare took over in 2018, the ED patient groups were the first to be on-boarded.
  • "Pierre Fabre's commitment to this groundbreaking program is rooted in our mutual dedication to the patient community.

Citryll Announces the Appointment of Maarten Kraan as Chief Medical Officer

Retrieved on: 
Tuesday, February 13, 2024
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Clinical Trials, Other Health, MSD, Therapy, Roche, Infliximab, Pfizer, AstraZeneca, Senior, Immune-mediated inflammatory diseases, Merck, Schering-Plough, CMO, Neutrophil, Research and development, Adalimumab, Inflammation, Belatacept, Leiden University, Stallergenes Greer, Bristol Myers Squibb, Abatacept, Rheumatoid arthritis, Hidradenitis suppurativa, Merck & Co., Patient, Pierre Fabre, Biology, Development, Pharmaceutical industry

Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.

Key Points: 
  • Citryll, a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Maarten Kraan, M.D., Ph.D., as Chief Medical Officer.
  • Prior to that, he held various senior medical and R&D positions at Pierre Fabre S.A., AstraZeneca, Roche and Bristol Myers-Squibb.
  • Dr. Kraan will replace Dr. Patrick Round, who will continue to support the company during the transition period.
  • Notably, Dr. Kraan was also involved in the development of Orencia (abatacept), Remicade (infliximab), Humira (adalimumab) and fostamatinib for rheumatoid arthritis.

Terran Biosciences announces exclusive licensing deal with Pierre Fabre for idazoxan; Terran completes key development milestones

Retrieved on: 
Friday, June 2, 2023
Drug Master File, Pierre Fabre, Half-life, Schizophrenia, Idazoxan, CMC, Clinical trial, Pharmacokinetics, DSM-IV codes, CNS, Plasma, Patient, XR, FDA, S.A.S, Safety, Pharmaceutical industry, Terran

The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.

Key Points: 
  • The deal features the novel lead compound idazoxan, a selective alpha 2 receptor antagonist, along with a portfolio of other compounds with a similar mechanism of action.
  • Idazoxan has been tested in multiple phase 3 clinical studies and has been dosed in over 1,000 patients across a variety of neuropsychiatric indications.
  • Dr. Sam Clark, Terran's founder and CEO remarked, "We are thrilled to partner with the team at Pierre Fabre and to push forward with the development of idazoxan and this pipeline of CNS compounds.
  • Given the strength of the human data to date, we believe idazoxan XR has the potential to revolutionize the treatment of patients with schizophrenia and other neuropsychiatric disorders."

Pierre Fabre announces start of EU marketing authorization application procedure for Vibegron in overactive bladder

Retrieved on: 
Monday, May 22, 2023
Contract management, Pierre Fabre, Quality of life, Single person, Gesellschaft mit beschränkter Haftung, EMA, OAB, BP, Urology, Patient, Overactive bladder, Heart rate, Urinary incontinence, Safety, Pharmaceutical industry, EU, Vibegron

CASTRES, France, May 22, 2023 /PRNewswire/ -- Following the exclusive licensing agreement with Urovant Sciences GmbH, Pierre Fabre announced today the start of the EU marketing authorization application procedure (centralized procedure) for Vibegron, a novel, potent, and selective human β3 adrenergic receptor (β 3-AR) agonist inducing muscle relaxation to increase bladder capacity and relieve symptoms of overactive bladder (OAB).

Key Points: 
  • CASTRES, France, May 22, 2023 /PRNewswire/ -- Following the exclusive licensing agreement with Urovant Sciences GmbH, Pierre Fabre announced today the start of the EU marketing authorization application procedure (centralized procedure) for Vibegron, a novel, potent, and selective human β3 adrenergic receptor (β 3-AR) agonist inducing muscle relaxation to increase bladder capacity and relieve symptoms of overactive bladder (OAB).
  • Results from this study confirm that Vibegron 75 mg had no statistically significant or clinically meaningful effects on BP or HR in patients with symptoms of OAB.
  • "The submission of the Vibegron application to the EMA is another important milestone for Pierre Fabre, which reinforces its long-standing commitment to the field of urology.
  • For more information about Pierre Fabre, please visit www.pierre-fabre.com .

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, April 4, 2023
Oncology, Health, General Health, Research, Science, Pharmaceutical, Biotechnology, Partnership, Gastrointestinal tract, Pierre Fabre, Neoplasm, Skin, Lung cancer, Mutation, Multimedia, NSCLC, Development, Patient, EGFR, Medicine, Health care, Financial toxicity, Therapy, Pharmaceutical industry, Scorpion

Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC").

Key Points: 
  • Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC").
  • Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241.
  • Pierre Fabre has a track-record in developing and commercializing cancer therapies for nearly four decades.
  • We recently focused our R&D efforts on targeted therapies and this partnership with Scorpion embodies this strategic move,” said Eric Ducournau, Chief Executive Officer of Pierre Fabre.

Scorpion Therapeutics and Pierre Fabre Announce Collaboration and License Agreement to Co-Develop and Commercialize STX-721 and STX-241 for Patients with EGFR Mutant Non-Small Cell Lung Cancer

Retrieved on: 
Tuesday, April 4, 2023
Partnership, Gastrointestinal tract, Pierre Fabre, Neoplasm, Biotechnology, Lung cancer, Mutation, NSCLC, Development, Patient, EGFR, Medicine, Health care, Pulmonary toxicity, Therapy, Skin, Pharmaceutical industry, Scorpion, Research

Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC").

Key Points: 
  • Discovered by Scorpion, STX-721 and STX-241 are potentially best-in-class inhibitors of EGFR mutations and potent treatment options for emergent and unmet medical needs in non-small cell lung cancer ("NSCLC").
  • Under the agreement, Scorpion will lead clinical development of STX-721 and Pierre Fabre will lead clinical development of STX-241.
  • "Our mission is to develop the next generation of transformational therapies and to deliver them to patients worldwide," said Axel Hoos, M.D., Ph.D., Chief Executive Officer of Scorpion.
  • Pierre Fabre has a track-record in developing and commercializing cancer therapies for nearly four decades.

Pierre Fabre to Commercialize and Distribute the First Approved Allogeneic T-cell Immunotherapy in Europe Following Transfer of the European Commission Marketing Authorization of EBVALLO™ (tabelecleucel)

Retrieved on: 
Wednesday, February 8, 2023
Health, Stem Cells, Other Health, Research, Science, Pharmaceutical, Biotechnology, ATRA, MA, European Commission, EBV, Pierre Fabre, Fabre, Civil service commission, Patient, PTLD, Bone marrow, EC, Multimedia, Rare, Pharmaceutical industry, EU

From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.

Key Points: 
  • From today, Pierre Fabre will lead all commercialization, distribution, medical and regulatory activities in Europe, Middle East, Africa and other selected markets.
  • Pierre Fabre is planning to launch EBVALLO™ in the first European countries during quarter one of 2023.
  • The EC marketing authorization is based on results from the pivotal Phase 3 ALLELE study and additional supportive studies.
  • Atara retains full rights to EBVALLO™ in other major markets, including North America, Asia Pacific, and Latin America.

Atara Biotherapeutics Announces $31 Million Royalty Interest Financing Agreement with HealthCare Royalty

Retrieved on: 
Tuesday, December 20, 2022
Professional Services, Oncology, Health, Finance, Pharmaceutical, Biotechnology, Security (finance), Patient, TCR, HLA, Northwest Biotherapeutics, Lymphatic system, Analysis, Biology, Autoimmune disease, EBV, Canadian Aviation Regulations, Form 10-K, Degenerative disease, Result, COVID-19, Marketing, Financial condition report, Multiple sclerosis, Autoimmunity, Hematological Cancer Research Investment and Education Act, Form, Pierre Fabre, ATRA, Pierre, Antigen, Epstein–Barr virus, Research, Cancer, Acquisition, European Commission, Pharmaceutical industry, EU

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo™ in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre.

Key Points: 
  • Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, has entered into a royalty interest financing agreement totaling $31 million with HealthCare Royalty (HCRx) for Ebvallo™ in Europe and other territories covered by Atara’s commercialization agreement with Pierre Fabre.
  • In exchange, HCRx will receive rights to specified royalties and milestones under the Pierre Fabre commercialization agreement for Europe and other territories.
  • HEALTHCARE ROYALTY® is a registered trademark of HealthCare Royalty Management, LLC in the U.S. and a trademark in other countries.
  • Improving patients’ lives is our mission and we will never stop working to bring transformative therapies to those in need.

Erasca Announces Clinical Trial Collaboration and Supply Agreement with Pierre Fabre to Evaluate ERAS-007 and Encorafenib Combination

Retrieved on: 
Wednesday, November 30, 2022
COVID-19, MAPK, Encorafenib, SAN, NSCLC, RAF, RTK, Large-cell lung carcinoma, Partnership, Pfizer, RAS, Patient, Progression-free survival, ERK1, BRAF, SHP2, Investment, Security (finance), GI, Annual report, Cancer, Pierre Fabre, Cetuximab, Research, ERK, ERK2, Clinical trial, CRC, Form 10-K, FDA, Pharmaceutical industry

SAN DIEGO, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced a clinical trial collaboration and supply agreement (CTCSA) with Pierre Fabre for the BRAF inhibitor encorafenib (BRAFTOVI®) within key international territories.

Key Points: 
  • Erasca will sponsor the trial, and Pierre Fabre will supply encorafenib in the Pierre Fabre territories which include Europe and Asia Pacific (excluding Japan and South Korea).
  • This partnership complements our existing CTCSA with Pfizer for encorafenib within the United States and other markets.
  • Encorafenib in combination with cetuximab was approved by the FDA in April 2020 for previously treated patients with BRAF V600E-mutant mCRC.
  • HERKULES-3 is a Phase 1b/2 master protocol clinical trial for ERAS-007 in combination with various agents in patients with GI cancers.